

# Zhengqiang Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3030434/publications.pdf>

Version: 2024-02-01

65  
papers

1,864  
citations

236612

25  
h-index

301761

39  
g-index

66  
all docs

66  
docs citations

66  
times ranked

1799  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design, Synthesis, Biochemical, and Antiviral Evaluations of C6 Benzyl and C6 Biarylmethyl Substituted 2-Hydroxyisoquinoline-1,3-diones: Dual Inhibition against HIV Reverse Transcriptase-Associated RNase H and Polymerase with Antiviral Activities. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 651-664.	2.9	112
2	Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3416-3419.	2.9	85
3	5- <i>S</i> -Silylated 1,2,3-triazolyl Thymidine Analogues as Inhibitors of West Nile Virus and Dengue Virus. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4016-4028.	2.9	67
4	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 467-479.	1.4	66
5	Synthesis of Highly Substituted Cyclopentenones via the [4 + 1] Cycloaddition of Nucleophilic Carbenes and Vinyl Ketenes. <i>Organic Letters</i> , 2003, 5, 263-264.	2.4	64
6	Clicking 3-Azidothymidine into Novel Potent Inhibitors of Human Immunodeficiency Virus. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8765-8780.	2.9	64
7	N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 63-67.	1.3	61
8	5-Arylideneethiothiazolidinones as Inhibitors of Tyrosyl DNA Phosphodiesterase I. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8671-8684.	2.9	56
9	3-Hydroxypyrimidine-2,4-diones as an Inhibitor Scaffold of HIV Integrase. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2282-2292.	2.9	54
10	Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5051-5062.	2.9	54
11	Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2734-2746.	2.9	52
12	Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 3587-3595.	1.4	50
13	[4 + 1] Cycloaddition of N-Heterocyclic Carbenes with Vinyl Isocyanates. <i>Organic Letters</i> , 2002, 4, 4289-4291.	2.4	44
14	Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4202-4211.	1.4	43
15	Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1293-1296.	1.0	40
16	3-Hydroxypyrimidine-2,4-dione-5- <i>N</i> -benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6136-6148.	2.9	40
17	3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2648-2659.	2.9	39
18	Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An <i>in vitro</i> and <i>in vivo</i> DMPK assessment. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1607-1616.	5.7	39

#	ARTICLE	IF	CITATIONS
19	Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5045-5056.	2.9	38
20	6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2400-2402.	1.0	37
21	Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H. <i>European Journal of Medicinal Chemistry</i> , 2017, 141, 149-161.	2.6	36
22	Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2. <i>ACS Chemical Biology</i> , 2016, 11, 1925-1933.	1.6	32
23	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 1113-1127.	5.7	32
24	Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2048-2061.	1.4	31
25	Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3275-3279.	1.0	28
26	6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 680-691.	2.6	28
27	6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 652-665.	2.6	27
28	Cutting into the Substrate Dominance: Pharmacophore and Structure-Based Approaches toward Inhibiting Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H. <i>Accounts of Chemical Research</i> , 2020, 53, 218-230.	7.6	27
29	Rotten to the core: antivirals targeting the HIV-1 capsid core. <i>Retrovirology</i> , 2021, 18, 41.	0.9	27
30	Synthesis and antiviral evaluation of 4- $\beta$ -(1,2,3-triazol-1-yl)thymidines. <i>MedChemComm</i> , 2014, 5, 603-608.	3.5	26
31	Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase. <i>European Journal of Medicinal Chemistry</i> , 2017, 133, 85-96.	2.6	23
32	Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
33	Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker. <i>European Journal of Medicinal Chemistry</i> , 2019, 166, 390-399.	2.6	22
34	Novel PF74-like small molecules targeting the HIV-1 capsid protein: Balance of potency and metabolic stability. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 810-822.	5.7	22
35	6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverse transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase. <i>European Journal of Medicinal Chemistry</i> , 2017, 128, 168-179.	2.6	21
36	The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells. <i>MSphere</i> , 2018, 3, .	1.3	21

#	ARTICLE	IF	CITATIONS
37	Inhibition of topoisomerase IIA (Top2 $\beta$ ) induces telomeric DNA damage and T cell dysfunction during chronic viral infection. <i>Cell Death and Disease</i> , 2020, 11, 196.	2.7	21
38	Triazolopyrimidine and triazolopyridine scaffolds as TDP2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 257-261.	1.0	20
39	Toward Structurally Novel and Metabolically Stable HIV-1 Capsid-Targeting Small Molecules. <i>Viruses</i> , 2020, 12, 452.	1.5	20
40	3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	19
41	Metal-chelating 3-hydroxypyrimidine-2,4-diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication. <i>Antiviral Research</i> , 2018, 152, 10-17.	1.9	19
42	A 2-Hydroxyisoquinoline-1,3-Dione Active-Site RNase H Inhibitor Binds in Multiple Modes to HIV-1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	17
43	Hydroxypyridonecarboxylic Acids as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease. <i>ChemMedChem</i> , 2018, 13, 1658-1663.	1.6	17
44	5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 179-192.	2.6	17
45	C-6 aryl substituted 4-quinolone-3-carboxylic acids as inhibitors of hepatitis C virus. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 4790-4800.	1.4	16
46	Chemical profiling of HIV-1 capsid-targeting antiviral PF74. <i>European Journal of Medicinal Chemistry</i> , 2020, 200, 112427.	2.6	16
47	Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. <i>DNA Repair</i> , 2020, 85, 102747.	1.3	15
48	The substrate-binding cap of the UDP-diacetylglucosamine pyrophosphatase LpxH is highly flexible, enabling facile substrate binding and product release. <i>Journal of Biological Chemistry</i> , 2018, 293, 7969-7981.	1.6	14
49	New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2). <i>European Journal of Pharmaceutical Sciences</i> , 2018, 118, 67-79.	1.9	14
50	Novel HIV-1 capsid-targeting small molecules of the PF74 binding site. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112626.	2.6	14
51	Discovery of New Small Molecule Hits as Hepatitis B Virus Capsid Assembly Modulators: Structure and Pharmacophore-Based Approaches. <i>Viruses</i> , 2021, 13, 770.	1.5	14
52	Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4669-4682.	2.9	13
53	Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores. <i>ACS Infectious Diseases</i> , 2019, 5, 750-758.	1.8	13
54	Design, Synthesis and Characterization of HIV-1 CA-Targeting Small Molecules: Conformational Restriction of PF74. <i>Viruses</i> , 2021, 13, 479.	1.5	11

#	ARTICLE	IF	CITATIONS
55	Molecular Dynamics Free Energy Simulations Reveal the Mechanism for the Antiviral Resistance of the M66I HIV-1 Capsid Mutation. <i>Viruses</i> , 2021, 13, 920.	1.5	11
56	Determinants of Active-Site Inhibitor Interaction with HIV-1 RNase H. <i>ACS Infectious Diseases</i> , 2019, 5, 1963-1974.	1.8	10
57	4-benzylideneisoquinoline-1,3(2H,4H)-diones as tyrosyl DNA phosphodiesterase 2 (TDP2) inhibitors. <i>Medicinal Chemistry Research</i> , 2021, 30, 371-386.	1.1	6
58	Discovery of N-benzyl hydroxypyridone carboxamides as a novel and potent antiviral chemotype against human cytomegalovirus (HCMV). <i>Acta Pharmaceutica Sinica B</i> , 2021, , .	5.7	5
59	Metal binding 6-arylthio-3-hydroxypyrimidine-2,4-diones inhibited human cytomegalovirus by targeting the pUL89 endonuclease of the terminase complex. <i>European Journal of Medicinal Chemistry</i> , 2021, 222, 113640.	2.6	5
60	4,5-Dihydroxypyrimidine Methyl Carboxylates, Carboxylic Acids, and Carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5830-5849.	2.9	4
61	Challenges and Opportunities in Hepatitis B Research. <i>ACS Infectious Diseases</i> , 2019, 5, 652-654.	1.8	1
62	Potency and metabolic stability: a molecular hybrid case in the design of novel PF74-like small molecules targeting HIV-1 capsid protein. <i>RSC Medicinal Chemistry</i> , 2021, 12, 2031-2044.	1.7	1
63	[4 + 1] Cycloaddition of N-Heterocyclic Carbenes with Vinyl Isocyanates.. <i>ChemInform</i> , 2003, 34, no.	0.1	0
64	Synthesis of Highly Substituted Cyclopentenones via the [4 + 1] Cycloaddition of Nucleophilic Carbenes and Vinyl Ketenes.. <i>ChemInform</i> , 2003, 34, no.	0.1	0
65	In honor of Professor Robert Vince on the occasion of his 80th birthday. <i>Medicinal Chemistry Research</i> , 2021, 30, 303-304.	1.1	0